A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)
NCT ID: NCT04626596
Last Updated: 2025-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
498 participants
INTERVENTIONAL
2020-11-19
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ENG implant
Participants will have the ENG 68 mg implant inserted and in place for 36 months before enrollment. The ENG implant will remain in place for an additional 24 months.
Radiopaque Etonogestrel (ENG) Implant
68 mg subdermal implant
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radiopaque Etonogestrel (ENG) Implant
68 mg subdermal implant
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Heterosexually active with a partner who is not known to be subfertile, sterilized, or infertile, and is seeking contraception for pregnancy.
* Palpable intact ENG implant in the upper inner-arm for 36 months from the date of insertion at the time of enrollment, and has documentation of the insertion date (for example, Nexplanon user card or medical record completed on the date of insertion).
* Does not desire a pregnancy within the 24 months after enrollment, is willing to continue use of the implant for an additional 24 months, and is not intending to use any other form of contraception (eg, condoms) from enrollment until after implant removal at 24 months post enrollment.
* Good physical and mental health in the medical judgment of the investigator.
* History of regular menstrual cycles of 21 to 35 days before the insertion of the ENG implant or before hormonal contraceptive use (which may have preceded the current implant use).
* Able and willing to adhere to all required study procedures, including study visits and eDiary entries, and not planning to relocate during the study.
Exclusion Criteria
* Known or suspected pregnancy at the time of screening or enrollment visit.
* History of subfertility or infertility.
* Breastfeeding.
* Untreated gonorrhea, chlamydia, or trichomonas or symptomatic vaginitis/cervicitis.
* Significantly abnormal cervical cytology (Pap) or pathology results either at screening or documented in the 36-month period prior to enrollment.
* Current use of an intrauterine device/intrauterine system (IUD/IUS).
* Presence of more than one ENG implant.
* Use of daily/monthly hormonal contraceptives, sex steroids, or GnRH agonist/antagonist within 3 months prior to enrollment.
* Use of injectable hormonal contraceptive with 3-month duration within 9 months prior to enrollment.
* Use of injectable GnRH agonist with 3-month duration within 10 months prior to enrollment .
* Use of medications that induce liver enzymes within 2 months prior to enrollment.
* Untreated or unresolved vaginal bleeding or spotting attributable to underlying pathology in the 12 months before screening.
* Frequent, prolonged, or excessive vaginal bleeding/spotting in the 12 months prior to screening which has not been evaluated to detect underlying pathology.
* History of venous thromboembolism or arterial thromboembolism, transient ischemic attack, angina pectoris, or claudication.
* Any condition associated with an increased risk of venous thromboembolism.
* Uncontrolled or severe hypertension at screening visit.
* Clinically significant liver disease, including active viral hepatitis or cirrhosis.
* History of malignancy within 5 years before screening, except treated skin cancer.
* History of sex steroid-influenced malignancies (eg, genital organs, breasts).
* History or presence of liver tumors (benign or malignant).
* Known allergy/sensitivity or contraindication to the ENG implant or lidocaine with epinephrine.
* History of drug or alcohol abuse or dependence within 24 months prior to enrollment. Routine use of alcohol or marijuana that is not considered abuse or dependence is not exclusionary.
* Use of an investigational drug within 2 months prior to enrollment. Long-term follow up of an investigational compound for COVID-19 is allowed 2 months after the last administered dose.
* Staff or immediate family members of the investigational site or Sponsor directly involved with this study.
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Organon and Co
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Lead
Role: STUDY_DIRECTOR
Organon and Co
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama Clinical Therapeutics (Site 0222)
Birmingham, Alabama, United States
Desert Star Family Planning (Site 0193)
Phoenix, Arizona, United States
Precision Trials (Site 0187)
Phoenix, Arizona, United States
Visions Clinical Research Tucson (Site 0134)
Tucson, Arizona, United States
Essential Access Health (Site 0163)
Los Angeles, California, United States
Matrix Clinical Research Inc (Site 0105)
Los Angeles, California, United States
University of California Los Angeles (Site 0119)
Los Angeles, California, United States
University of California, Davis (Site 0124)
Sacramento, California, United States
Stanford University (Site 0112)
Stanford, California, United States
Planned Parenthood of the Rocky Mountains (Site 0196)
Denver, Colorado, United States
Comprehensive Womens Health Center (Site 0194)
Denver, Colorado, United States
Physicians' Research Options, LLC (Site 0166)
Lakewood, Colorado, United States
University Of Florida (Site 0144)
Jacksonville, Florida, United States
Emerald Coast Obstetrics and Gynecology (Site 0203)
Panama City, Florida, United States
Lenus Research & Medical Group Llc (Site 0102)
Sweetwater, Florida, United States
Comprehensive Clinical Trials LLC (Site 0101)
West Palm Beach, Florida, United States
Mount Vernon Clinical Research (Site 0111)
Sandy Springs, Georgia, United States
Rosemark (Site 0177)
Idaho Falls, Idaho, United States
Planned Parenthood of Illinois (PPIL) (Site 0200)
Chicago, Illinois, United States
Indiana University (Site 0220)
Indianapolis, Indiana, United States
McFarland Clinic, PC (Site 0217)
Ames, Iowa, United States
Cypress Medical Research Center (Site 0226)
Wichita, Kansas, United States
Southern Clinical Research Associates (Site 0219)
Metairie, Louisiana, United States
Johns Hopkins Bayview Medical Center (Site 0225)
Baltimore, Maryland, United States
Boston University Medical Center (Site 0167)
Boston, Massachusetts, United States
Planned Parenthood League of Massachusetts (Site 0135)
Boston, Massachusetts, United States
Michigan Medicine (Site 0108)
Ann Arbor, Michigan, United States
Saginaw Valley Medical Research Group, LLC (Site 0198)
Saginaw, Michigan, United States
Planned Parenthood of North Central States (PPNCS) (Site 0113)
Minneapolis, Minnesota, United States
Metro Jackson OBGYN/SKYCRNG (Site 0233)
Jackson, Mississippi, United States
Planned Parenthood of the Saint Louis Region & Southwest Missouri (Site 0158)
St Louis, Missouri, United States
Washington University (Site 0129)
St Louis, Missouri, United States
Office of Edmond Pack, MD (Site 0168)
Las Vegas, Nevada, United States
Capital Health OB/GYN- Lawrenceville (Site 0190)
Lawrenceville, New Jersey, United States
Albuquerque Clinical Trials (Site 0210)
Albuquerque, New Mexico, United States
Bosque Women's Care (Site 0211)
Albuquerque, New Mexico, United States
Icahn School of Medicine at Mount Sinai (Site 0155)
New York, New York, United States
Columbia Univ. Medical Center (Site 0118)
New York, New York, United States
Montefiore Medical Center (Site 0103)
The Bronx, New York, United States
Carolina Women's Research and Wellness Center (Site 0154)
Durham, North Carolina, United States
Eastern Carolina Women's Center (Site 0159)
New Bern, North Carolina, United States
Velocity Clinical Research, Cincinnati (Site 0230)
Cincinnati, Ohio, United States
The Ohio State University (Site 0176)
Columbus, Ohio, United States
HWC Women's Research Center (Site 0199)
Englewood, Ohio, United States
Oregon Health Sciences University Hospital (Site 0128)
Portland, Oregon, United States
OB/GYN Associates of Erie (Site 0183)
Erie, Pennsylvania, United States
University of Pittsburgh - Magee Womens Hospital (Site 0100)
Pittsburgh, Pennsylvania, United States
Palmetto Clinical Research (Site 0133)
Summerville, South Carolina, United States
University of Tennessee Medical Center Knoxville (Site 0218)
Knoxville, Tennessee, United States
Gadolin Research (Site 0232)
Beaumont, Texas, United States
Signature Gyn Services (Site 0201)
Fort Worth, Texas, United States
Planned Parenthood of the Gulf Coast (Site 0106)
Houston, Texas, United States
University of Texas Health Science Center (Site 0178)
Houston, Texas, United States
Centex Studies, Inc. (Site 0171)
Houston, Texas, United States
Advances in Health, Inc. (Site 0209)
Pearland, Texas, United States
Tekton Research - Floyd Curl Drive (Site 0228)
San Antonio, Texas, United States
Physicians' Research Options, LLC (Site 0204)
Pleasant Grove, Utah, United States
JBR Clinical Research (Site 0174)
Salt Lake City, Utah, United States
Tidewater Clinical Research Inc (Site 0162)
Norfolk, Virginia, United States
Eastern Virginia Medical School (Site 0146)
Norfolk, Virginia, United States
Multicare Health System Institute for Research and Innovation (Site 0188)
Cheney, Washington, United States
Seattle Women's: Health, Research, Gynecology (Site 0149)
Seattle, Washington, United States
Planned Parenthood Great Northwest, Hawai'i, Alaska, Indiana, Kentucky (Site 0110)
Seattle, Washington, United States
North Spokane Women's Clinic (Site 0137)
Spokane, Washington, United States
Advance Medical Concept PSC (Site 0313)
Cidra, PR, Puerto Rico
Clinical Research Puerto Rico Inc (Site 0302)
San Juan, PR, Puerto Rico
FDI Clinical Research (Site 0305)
San Juan, PR, Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-001232-95
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
MK-8415-060
Identifier Type: OTHER
Identifier Source: secondary_id
8415-060
Identifier Type: -
Identifier Source: org_study_id